The abstract is read at the publisher; the summary is JClub's.
Focused ultrasound–enhanced carboplatin delivery plus stereotactic radiotherapy in F98 glioma-bearing rats increased median survival by up to 122% versus untreated controls.
- Why it matters: Platinum chemotherapy is limited in glioblastoma by poor penetration across the blood-brain and blood-tumor barriers, reducing both cytotoxic and radiosensitizing impact.
- What they did: Rats received 15 Gy RT, carboplatin, and/or focused ultrasound, with BBB/BTB disruption confirmed by MRI and carboplatin uptake measured by inductively coupled plasma mass spectrometry and synchrotron X-ray fluorescence.
- The result: The combined FUS + carboplatin + RT regimen produced the strongest tumor control, reduced necrotic core expansion, transiently increased perfusion, and showed platinum distribution that closely correlated with MRI signal enhancement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.